EFPIA - Articles and news items

A strong EU IP framework guarantees future innovation for patients

Industry news / 19 May 2017 / European Federation of Pharmaceutical Industries and Associations (EFPIA)

Intellectual Property (IP) could be considered the foundation for pharmaceutical innovation. In healthcare, innovation means improved health outcomes: avoiding illness; slowing disease progression; improving patients’ lives; and reducing overall costs for healthcare systems. With over 80 medicines approved every year – including some 30 new, approved substances – and over 7,000 medicines currently in development, […]

EFPIA releases statement on Brexit

Industry news / 30 June 2016 / Victoria White, Digital Content Producer

In the statement, EFPIA underscores the importance of ensuring that the patient is at the centre of all subsequent decisions…

Reactions to the EU Referendum

Industry news / 24 June 2016 / Victoria White, Digital Content Producer

The BioIndustry Association and EFPIA have reacted to the news that Britain has voted to leave the European Union (EU)…

Clinical trials – a rigorous framework for trial authorisation and patient safety monitoring

Blog / 26 February 2016 / Sini Eskola, Director, European Federation of Pharmaceutical Industries and Associations (EFPIA)

This review looks at the steps needed to complete clinical trials in the European Union (EU) and describes the rigorous regulatory framework involved in clinical research…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+